Companion Society Meetings

Endocrine Pathology Society

Clinical Impact of Surgical Pathology in Endocrine Tumors

Saturday, March 17, 2018, 7:00 - 10:00 PM

Session Credits:

3 CME and 2.5 SAMs


Virginia A. LiVolsi, MD, University of Pennsylvania, Philadelphia, PA
Marco Volante, MD, University of Turin, Turin, Italy

Course Description:

Recently, many important clinico-pathologic and molecular studies as well as books have been published on endocrine tumors. These include the upcoming AJCC staging systems, the new WHO book on endocrine tumors, novel management guidelines emanating from respected endocrine societies and large scale genomic projects like the TCGA. The clinical impact of these advances on diagnosis, prognosis and therapy is considerable. The histopathologic, molecular and outcome data will be reviewed and their influence on the daily pathology practice emphasized.

Learning Objectives:

Upon completion of this educational activity, the learner will be able to:

  • Understand the impact of the new TNM staging system for thyroid carcinomas on prognosis and therapy
  • Appreciate the clinical implications of specific histopathologic parameters such as vascular invasion and papillary carcinoma variants
  • Have an overview of the main prognostic features and molecular events in poorly differentiated thyroid carcinomas and their impact on classification, risk stratification and therapy
  • Understand the tools for risk stratification of pheochromocytoma and paraganglioma
  • Update their knowledge in the emerging role of pathology in predicting response to target therapies and immunotherapy


7:00 PM Presentation of the Hubert Wolfe Award
Arthur Tischler, MD, Tufts University, Boston, MA
7:10 AM New TNM Staging in Thyroid Cancer
Ronald A. Ghossein, MD, Memorial Sloan Kettering Cancer Center, New York, NY
7:35 PM Clinically Relevant Prognostic Parameters in Differentiated Thyroid Cancer
Justine A. Barletta, MD, Brigham and Women's Hospital, Boston, MA
8:00 PM Poorly Differentiated Thyroid Carcinoma: Revised Definition, Molecular Profile and Histotype-specific Prognostic Factors
Giovanni Tallini, MD, University of Bologna School of Medicine, Bologna, Italy
8:25 PM Risk Stratification of Pheochromocytoma and Paraganglioma
Noriko Kimura, MD, PhD, National Hospital Organization, Kawahara, Hakodate, Hokkaido, Japan
8:50 PM Emerging Role of Predictive Pathology in Endocrine Tumors
Marco Volante, MD, University of Turin, Turin, Italy
9:15 PM Summary and Conclusions
Ricardo Lloyd, University of Wisconsin, Madison, WI


Continuing Medical Education and Maintenance of Certification

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The United States and Canadian Academy of Pathology and American Association of Neuropathologists. The United States and Canadian Academy of Pathology is accredited by the ACCME to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABP) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABP requirements for Maintenance of Certification (MOC). Physicians must take and pass the post-test in order to claim SAMs credit.

Physicians can earn a maximum of 2.5 SAM credit hours.


Return to 2018 Annual Meeting Companion Society Meetings Page


view more